Use of IMP3 in Identification of Carcinoma in Fine Needle Aspiration Biopsies of Pancreas

Yantiss, Rhonda K.; Cosar, Ediz F.; Fischer, Andrew H.

doi:10.1159/000325470

Cited by 39 publications

(31 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The sensitivity and specificity of MUC1, was 96 and 94%, respectively [11]. Yantiss et al found that KOC had a diagnostic sensitivity of 97% for the diagnosis of PDA [3], and that IMP3 had a sensitivity of 92% and specificity of 100% [2]. Bhanot et al [8] demonstrated a gradual increase in cytoplasmic survivin expression from low-grade PanIN to high-grade PanIN and to PDA.…”

Section: Discussionmentioning

confidence: 99%

“…The initial evaluation of pancreatic lesions frequently involves minimally invasive techniques to obtain diagnostic samples, such as endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) and cytologic brushing of the common bile duct, pancreatic duct and ampulla of Vater [2,3]. The potential advantage of EUS-FNA over percutaneous FNA includes an enhanced staging capability for assessing locally advanced disease and fewer concerns about tumor seeding of the needle tract [4].…”

Section: Introductionmentioning

confidence: 99%

“…Although the cytologic criteria for pancreatic ductal adenocarcinoma (PDA) on FNA are well established, making a diagnosis of well-differentiated PDA in a patient with co-existing chronic pancreatitis remains challenging in daily practice and is associated with significant therapeutic implications. Recently, several biomarkers have been identified which can be used as diagnostic adjuncts to FNA cytology to improve sensitivity and specificity of the diagnosis of PDA [2,3,4,5,6,7,8,9,10,11,12,13,14,15,16]. …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

S100P and XIAP Expression in Pancreatic Ductal Adenocarcinoma: Potential Novel Biomarkers as a Diagnostic Adjunct to Fine Needle Aspiration Cytology

Kosarac¹,

Takei²,

Zhai

et al. 2011

Acta Cytologica

View full text Add to dashboard Cite

Objective: The usefulness of 2 novel biomarkers in pancreatic surgical and cytological specimens that could reliably differentiate non-neoplastic pancreatic duct and benign gut epithelium from pancreatic ductal adenocarcinoma (PDA) was evaluated. Study Design: A total of 14 pancreatic resection specimens (RSs), 23 endoscopic ultrasound-guided fine needle aspirations (EUS-FNAs) of PDA and 8 benign pancreatic EUS-FNAs were selected. Twelve of 14 RSs had corresponding EUS-FNAs with cell blocks (CBs). Non-neoplastic pancreatic tissue, including chronic pancreatitis, was evaluated in all RSs. Immunohistochemical stains for S100P and X-linked inhibitor of apoptosis protein (XIAP) were performed on tissue and CB sections. Staining intensity (0 no staining; 1+ weak; 2+ moderate; 3+ strong) and proportion of positive cells (less than 10% negative; 1+ 10–25%; 2+ 26–75%; 3+ greater than 75%) were assessed. Positive staining was defined as ≧10% cells with at least 1+ intensity. Results: The sensitivity and specificity of S100P and XIAP immunoreactivity for a diagnosis of PDA in RSs were both 100%. In contrast, the sensitivity and specificity in EUS-FNA CBs of S100P were 78.2 and 87.5% and of XIAP 82.6 and 50.0%, respectively. The combined sensitivity of S100P and XIAP was 100% in 12 RSs and 83.3% in the corresponding EUS-FNA CBs. Conclusion: Two novel biomarkers have very high sensitivity and specificity in the diagnosis of PDA in RSs. S100P has slightly lower sensitivity and higher specificity of PDA than XIAP in EUS-FNA specimens. We recommend using both biomarkers as cytological diagnostic adjuncts, especially in difficult cases of well-differentiated PDA versus reactive ductal epithelium.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

S100P and XIAP Expression in Pancreatic Ductal Adenocarcinoma: Potential Novel Biomarkers as a Diagnostic Adjunct to Fine Needle Aspiration Cytology

Kosarac¹,

Takei²,

Zhai

et al. 2011

Acta Cytologica

View full text Add to dashboard Cite

show abstract

“…Because IMP3 is overexpressed in malignant tumors but is rarely detectable in normal adult tissues, immunohistochemical analysis of IMP3 expression can be used to differentiate benign and malignant processes [23,24,25]. However, studies on the usefulness of IMP3 for the detection of malignant cells in effusions are limited [26,27,28].…”

Section: Introductionmentioning

confidence: 99%

Insulin-Like Growth Factor-II mRNA-Binding Protein 3 Expression in Effusion Cytology: A Marker for Metastatic Adenocarcinoma Cells and a Potential Prognostic Indicator in Gastric Adenocarcinoma

Kim

Lee

et al. 2014

Acta Cytologica

View full text Add to dashboard Cite

Objective: The aim of our study was to identify the diagnostic value of insulin-like growth factor-II mRNA-binding protein 3 (IMP3) in distinguishing metastatic adenocarcinoma cells (MAC) from reactive mesothelial cells (RMC) in effusions. We also investigated the role of IMP3 as a prognostic indicator for patients with malignant effusion. Study Design: A total of 156 cell block specimens, including 116 malignant effusions with MAC and 40 benign effusions with RMC, were subjected to immunocytochemical staining for IMP3. Results: Immunocytochemical studies showed positive staining for IMP3 in 91 of 116 (78.4%) cases of MAC and in 3 of 40 (7.5%) cases of RMC. With regard to distinguishing MAC from RMC, the IMP3 reactivity was found to be 78.4% sensitive and 92.5% specific with a positive predictive value of 96.8% and a negative predictive value of 59.7%. Diffuse IMP3 expression (>25%) in MAC from patients with gastric adenocarcinoma was associated with shorter survival (p = 0.001). Conclusion: Our data suggest that IMP3 is a helpful marker for differentiating MAC from RMC, and that diffuse IMP3 expression is a poor prognostic indicator in patients with gastric adenocarcinoma and malignant effusion.

show abstract

“…Cytoplasmic positivity has been demonstrated in 71% to 97% of pancreatic ductal adenocarcinomas in various studies including cytology specimens, 162,167,[172][173][174][175][176][177] 82% of gallbladder adenocarcinomas, 168,178 and 50% to 92% of a d enoca rcino ma s o f ex tr a hep a tic b ile ducts. 169,170,[178][179][180] Intrahepatic cholangiocarcinomas also overexpress IMP3 at a high frequency (82%-90%), 167,181 but lower frequencies (37%-41%) are also reported.…”

mentioning

confidence: 99%

Practical Immunohistochemistry in Neoplastic Pathology of the Gastrointestinal Tract, Liver, Biliary Tract, and Pancreas

Wang¹,

Kim²,

Koo³

et al. 2017

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Context.— Immunomarkers with diagnostic, therapeutic, or prognostic values have been increasingly used to maximize the benefits of clinical management of patients with neoplastic diseases of the gastrointestinal tract, liver, biliary tract, and pancreas. Objectives.— To review the characteristics of immunomarkers that are commonly used in surgical pathology practice for neoplasms of the gastrointestinal tract, liver, biliary tract, and pancreas, and to summarize the clinical usefulness of immunomarkers that have been discovered in recent years in these fields. Data Sources.— Data sources include literature review, authors' research data, and personal practice experience. Conclusions.— Immunohistochemistry is an indispensable tool for the accurate diagnosis of neoplastic diseases of the gastrointestinal tract, liver, biliary tract, and pancreas. Useful immunomarkers are available to help distinguish malignant neoplasms from benign conditions, determine organ origins, and subclassify neoplasms that are morphologically and biologically heterogeneous. Specific immunomarkers are also available to help guide patient treatment and assess disease aggressiveness, which are keys to the success of personalized medicine. Pathologists will continue to play a critical role in the discovery, validation, and application of new biomarkers, which will ultimately improve patient care.

show abstract

Use of IMP3 in Identification of Carcinoma in Fine Needle Aspiration Biopsies of Pancreas

Cited by 39 publications

References 22 publications

S100P and XIAP Expression in Pancreatic Ductal Adenocarcinoma: Potential Novel Biomarkers as a Diagnostic Adjunct to Fine Needle Aspiration Cytology

S100P and XIAP Expression in Pancreatic Ductal Adenocarcinoma: Potential Novel Biomarkers as a Diagnostic Adjunct to Fine Needle Aspiration Cytology

Insulin-Like Growth Factor-II mRNA-Binding Protein 3 Expression in Effusion Cytology: A Marker for Metastatic Adenocarcinoma Cells and a Potential Prognostic Indicator in Gastric Adenocarcinoma

Practical Immunohistochemistry in Neoplastic Pathology of the Gastrointestinal Tract, Liver, Biliary Tract, and Pancreas

Contact Info

Product

Resources

About